MARKET

HEPA

HEPA

Hepion Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.860
-0.180
-5.92%
Closed 16:00 11/13 EST
OPEN
2.980
PREV CLOSE
3.040
HIGH
3.080
LOW
2.800
VOLUME
98.14K
TURNOVER
--
52 WEEK HIGH
40.25
52 WEEK LOW
2.000
MARKET CAP
9.88M
P/E (TTM)
-0.0426
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of HEPA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

HEPA News

  • Hepion Pharmaceuticals to Present at The Liver Meeting(R) 2019
  • ACCESSWIRE.6d ago
  • Hepion Pharmaceuticals' CRV431 Reduces Liver Fibrosis in a Western Diet Model of NASH
  • ACCESSWIRE.6d ago
  • Hepion Pharmaceuticals to Present on CRV431 at the 3rd Annual NASH Summit
  • ACCESSWIRE.10/23 21:15
  • Mid-Afternoon Market Update: Crude Oil Up Over 1%; Syros Pharmaceuticals Shares Slide
  • Benzinga.10/17 19:07

More

Industry

Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.16%

Hot Stocks

Name
Price
%Change

About HEPA

Hepion Pharmaceuticals Inc., formerly ContraVir Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company. The Company is focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection. Its lead oral drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. CRV431 is also being developed for viral hepatitis-induced liver disease. CRV431 targets multiple biochemical pathways involved in the progression of liver disease.
More

Webull offers Hepion Pharmaceuticals Inc (HEPA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.